Daniel D. Shoemaker
2020
In 2020, Daniel D. Shoemaker earned a total compensation of $2.5M as Chief Scientific Officer at Fate Therapeutics, a 13% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $195,000 |
|---|---|
| Option Awards | $1,324,347 |
| Salary | $390,000 |
| Stock Awards | $549,750 |
| Total | $2,459,097 |
Shoemaker received $1.3M in option awards, accounting for 54% of the total pay in 2020.
Shoemaker also received $195K in non-equity incentive plan, $390K in salary and $549.8K in stock awards.
Rankings
In 2020, Daniel D. Shoemaker's compensation ranked 4,626th out of 13,090 executives tracked by ExecPay. In other words, Shoemaker earned more than 64.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,626 out of 13,090 | 65th |
Division Manufacturing | 1,881 out of 5,621 | 67th |
Major group Chemicals And Allied Products | 735 out of 2,254 | 67th |
Industry group Drugs | 630 out of 1,954 | 68th |
Industry Biological Products, Except Diagnostic Substances | 149 out of 411 | 64th |
Source: SEC filing on April 21, 2021.
Shoemaker's colleagues
We found four more compensation records of executives who worked with Daniel D. Shoemaker at Fate Therapeutics in 2020.